2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Alcohol Drinking
11
Pancreatic Neoplasms
7
Neoplasms
5
Smoking Cessation
4
Pancreatic Cyst
4
Cancer Pain
4
Agnosia
4
Smoking
3
Pain
3
Depression
3
Prostatic Neoplasms
2
Postoperative Complications
2
Neoplasms, Cystic, Mucinous, and Serous
2
Multiple Endocrine Neoplasia Type 1
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia
2
Infections
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Condylomata Acuminata
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Cardiovascular Diseases
2
Breast Neoplasms
2
Brain Neoplasms
2
Alcoholism
2
Wounds and Injuries
1
Warts
1
Interventions
Trastuzumab
628
Paclitaxel
577
Cyclophosphamide
555
Docetaxel
485
Capecitabine
402
Letrozole
376
Fulvestrant
327
Doxorubicin
294
Carboplatin
279
Tamoxifen
275
Anastrozole
243
exemestane
228
Radiotherapy
218
Epirubicin
211
Bevacizumab
196
palbociclib
189
pertuzumab
186
Vinorelbine
167
Lapatinib
167
Gemcitabine
166
pembrolizumab
162
Surveys and Questionnaires
139
Exercise
136
Magnetic Resonance Spectroscopy
123
Fluorouracil
119
Blood Specimen Collection
118
eribulin
117
Albumin-Bound Paclitaxel
117
Drug Therapy
111
130-nm albumin-bound paclitaxel
111
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Ethanol
×
Clear all
NCT04007549
2024-11-19
IBMC
Institut Bergonié
Phase NA
Withdrawn
NCT01698918
2023-05-03
BOLERO-4
Novartis
Phase 2
Completed
202 enrolled
19 charts